VIGAMOX Drug Patent Profile
✉ Email this page to a colleague
When do Vigamox patents expire, and when can generic versions of Vigamox launch?
Vigamox is a drug marketed by Harrow Eye and is included in one NDA.
The generic ingredient in VIGAMOX is moxifloxacin hydrochloride. There are eighteen drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the moxifloxacin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vigamox
A generic version of VIGAMOX was approved as moxifloxacin hydrochloride by TEVA PHARMS USA on February 18th, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VIGAMOX?
- What are the global sales for VIGAMOX?
- What is Average Wholesale Price for VIGAMOX?
Summary for VIGAMOX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 111 |
| Clinical Trials: | 33 |
| Patent Applications: | 1,594 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VIGAMOX |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIGAMOX |
| What excipients (inactive ingredients) are in VIGAMOX? | VIGAMOX excipients list |
| DailyMed Link: | VIGAMOX at DailyMed |
Recent Clinical Trials for VIGAMOX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Kafrelsheikh University | Phase 4 |
| Benha University | Phase 1 |
| University of Campinas, Brazil | Phase 2 |
Pharmacology for VIGAMOX
| Drug Class | Quinolone Antimicrobial |
Paragraph IV (Patent) Challenges for VIGAMOX
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VIGAMOX | Ophthalmic Solution/Drops | moxifloxacin hydrochloride | 0.5% | 021598 | 1 | 2005-12-22 |
US Patents and Regulatory Information for VIGAMOX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Eye | VIGAMOX | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 021598-001 | Apr 15, 2003 | AT1 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIGAMOX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Harrow Eye | VIGAMOX | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 021598-001 | Apr 15, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Harrow Eye | VIGAMOX | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 021598-001 | Apr 15, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Harrow Eye | VIGAMOX | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 021598-001 | Apr 15, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Harrow Eye | VIGAMOX | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 021598-001 | Apr 15, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Harrow Eye | VIGAMOX | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 021598-001 | Apr 15, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIGAMOX
See the table below for patents covering VIGAMOX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Ireland | 970856 | ⤷ Sign Up | |
| Japan | 2009007375 | ANTIBIOTIC COMPOSITION FOR TREATING EYE, EAR AND NOSE | ⤷ Sign Up |
| Austria | 292127 | ⤷ Sign Up | |
| Indonesia | 22625 | ⤷ Sign Up | |
| European Patent Office | 2269602 | Compositions antibiotiques destinees au traitement des oreilles (Antibiotic compositions for treatment of the ear) | ⤷ Sign Up |
| South Africa | 8905366 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VIGAMOX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0350733 | SPC/GB03/034 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313 |
| 0780390 | PA2004012 | Lithuania | ⤷ Sign Up | PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-__ 1,4-DIHIDRO-8-METOKSI-7-[(4AS, 7AS)-OKTAHIDRO-6H-PIROLO[3,4-B]PIRIDIN_-6-IL]-4-OKSO-3-CHINOLINKARBOKSIRûGðTIES HIDROCHLORIDAS) |
| 0350733 | C300111 | Netherlands | ⤷ Sign Up | PRODUCT NAME: MOXIFLOXACINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER MOXIFLOXACINEHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 28118 RVG 28119 20021017; FIRST REGISTRATION: DE 45263.00.00 19990621 |
| 0780390 | PA2004012,C0780390 | Lithuania | ⤷ Sign Up | PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-1,4-DIHIDRO-8-METOKSI-7-((4AS, 7AS)-OKTAHIDRO-6H-PIROLO(3,4-B)PIRIDIN-6-IL)-4-OKSO-3-CHINOLINKARBOKSIRUGSTIES HIDROCHLORIDAS); REGISTRATION NO/DATE: 04/8383/3 20040309 |
| 0350733 | 300111 | Netherlands | ⤷ Sign Up | |
| 0350733 | 11/2000 | Austria | ⤷ Sign Up | PRODUCT NAME: MOXIFLOXACIN, DESSEN PHARMAZEUTISCH VERWENDBARE HYDRATE UND SAEUREADDITIONSSALZE, DESSEN ALKALI-ERDALKALI-SILBER- UND GUANIDINIUMSALZE, SOWIE DESSEN C1 - C4 ALKYL- ODER; NAT. REGISTRATION NO/DATE: 1-23494, 1-23495, 1-23496 20000215; FIRST REGISTRATION: DE 45263.00.00 19990621 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
